• K N Kose, S Yilmaz, U Noyan, B Kuru, H S Yildirim, O B Agrali, H O Ozener, and L Kuru.
• Department of Periodontology, Faculty of Dentistry, Marmara University, Istanbul, Turkey.
• Niger J Clin Pract. 2020 Apr 1; 23 (4): 561-567.

BackgroundAmlodipine, calcium channel blocker (CCB), is used in the management of cardiovascular diseases which causes gingival overgrowth (GO). The growth factors may have a role in the pathogenesis of amlodipine-induced GO.ObjectivesThis pilot study aimed to investigate the growth factors including transforming growth factor-b1 (TGF-b1), platelet-derived growth factor-BB (PDGF-BB), and basic fibroblast growth factor (bFGF) in gingival crevicular fluid (GCF) of patients with amlodipine-induced GO and compare with of healthy subjects.MethodsGCF samples were collected from 56 sites presenting GO (GO + group) and from 38 sites not presenting GO (GO- group) of 5 patients using amlodipine for more than one year, and from 45 sites (control group) of 5 healthy subjects. The levels of TGF-b1, PDGF-BB, and bFGF were determined by using ELISA kits.ResultsThe mean concentration of TGF-b1 in GCF samples of GO + group (9.50 ± 7.30 ng/ml) was higher than both GO- group (2.07 ± 0.50 ng/ml) and control group (2.74 ± 1.01 ng/ml) (P = 0.014). No significant difference was found among the groups in the GCF levels of PDGF-BB (P = 0.767). bFGF was detected in only 33% of the sites from patients.ConclusionThese preliminary results suggest that TGF-b1 may play a crucial role in the pathogenesis of amlodipine-induced GO.

16 keywords...

hide…